Antonio Sacco

List of Publications by Citations

148 papers	4,828 citations	36 h-index	69 g-index
150 ext. papers	5,525 ext. citations	4.1 avg, IF	4.59 L-index

#	Paper	IF	Citations
148	BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. *Journal of Clinical Investigation*, **2013**, 123, 1542-55	15.9	555
147	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. *Blood*, **2009**, 113, 4341-51	2.2	354
146	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood*, **2009**, 113, 6669-80	2.2	265
145	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. *Blood*, **2012**, 119, 5782-94	2.2	234
144	Engineered nanomedicine for myeloma and bone microenvironment targeting. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10287-92	11.5	204
143	Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood*, **2017**, 129, 2429-2436	2.2	161
142	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood*, **2014**, 123, 4120-31	2.2	150
141	Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. *Journal of Clinical Oncology*, **2009**, 27, 250-5	2.2	129
140	Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. *Cancer Research* , **2009**, 69, 3579-88	10.1	128
139	LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. *Blood*, **2012**, 120, 1678-86	2.2	116
138	Metabolic signature identifies novel targets for drug resistance in multiple myeloma. *Cancer Research*, **2015**, 75, 2071-82	10.1	112
137	Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. *Clinical Cancer Research*, **2010**, 16, 1033-41	12.9	105
136	SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. *Blood*, **2008**, 112, 150-8	2.2	104
135	Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. *Blood*, **2012**, 120, 3519-29	2.2	100
134	microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. *Blood* , **2010**, 116, 1506-14	2.2	99
133	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. *Blood*, **2014**, 124, 3250-9	2.2	98
132	microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. *Blood*, **2009**, 113, 4391-402	2.2	98

131	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. *Cell Reports*, **2015**, 12, 622-35	10.6	94
130	RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. *Blood*, **2009**, 114, 619-29	2.2	94
129	SDF-1 inhibition targets the bone marrow niche for cancer therapy. *Cell Reports*, **2014**, 9, 118-128	10.6	93
128	Targeting NF-kappaB in Waldenstrom macroglobulinemia. *Blood*, **2008**, 111, 5068-77	2.2	92
127	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. *Blood*, **2010**, 115, 559-69	2.2	88
126	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. *Blood*, **2012**, 119, 1468-78	2.2	84
125	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. *Blood*, **2014**, 124, 1765-76	2.2	80
124	Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. *Blood*, **2010**, 115, 4051-60	2.2	69
123	Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. *Blood*, **2008**, 111, 4752-63	2.2	69
122	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Reports*, **2017**, 19, 218-224	10.6	67
121	Defining the role of TORC1/2 in multiple myeloma. *Blood*, **2011**, 118, 6860-70	2.2	64
120	Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrm's macroglobulinemia. *Clinical Cancer Research*, **2008**, 14, 1849-58	12.9	64
119	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. *Molecular Cancer Therapeutics*, **2018**, 17, 1454-1463	6.1	49
118	Pyk2 promotes tumor progression in multiple myeloma. *Blood*, **2014**, 124, 2675-86	2.2	48
117	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. *Journal of Clinical Investigation*, **2018**, 128, 2487-2499	15.9	48
116	Genomic Landscape of Waldenstrm Macroglobulinemia and Its Impact on Treatment Strategies. *Journal of Clinical Oncology*, **2020**, 38, 1198-1208	2.2	40
115	Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. *Clinical Cancer Research*, **2011**, 17, 1753-64	12.9	38
114	Targeting vasculogenesis to prevent progression in multiple myeloma. *Leukemia*, **2016**, 30, 1103-15	10.7	37

113	Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. *Endocrinology*, **2017**, 158, 3369-3385	4.8	36
112	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. *Cancer Research*, **2016**, 76, 463-71	10.1	31
111	Global epigenetic regulation of microRNAs in multiple myeloma. *PLoS ONE*, **2014**, 9, e110973	3.7	28
110	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. *Oncotarget*, **2010**, 1, 578-582	3.3	28
109	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. *Leukemia*, **2015**, 29, 2338-46	10.7	27
108	Platelets Enhance Multiple Myeloma Progression via IL-1 Upregulation. *Clinical Cancer Research*, **2018**, 24, 2430-2439	12.9	26
107	Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. *Clinical Cancer Research*, **2012**, 18, 91-104	12.9	25
106	Exosomes in Tumor Angiogenesis. *Methods in Molecular Biology*, **2016**, 1464, 25-34	1.4	24
105	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. *Blood*, **2009**, 113, 626-34	2.2	20
104	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress. *Cancer Research*, **2020**, 80, 2340-2354	10.1	18
103	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. *Current Osteoporosis Reports*, **2017**, 15, 499-506	5.4	18
102	The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. *British Journal of Haematology*, **2008**, 142, 775-85	4.5	18
101	FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. *Clinical Cancer Research*, **2011**, 17, 4389-99	12.9	17
100	Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. *Clinical Cancer Research*, **2009**, 15, 6035-41	12.9	16
99	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. *Oncotarget*, **2010**, 1, 578-82	3.3	16
98	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstrm macroglobulinemia. *Blood*, **2016**, 127, 2598-606	2.2	16
97	microRNA aberrations in Waldenstrm macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 205-7	2	14
96	Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. *American Journal of Hematology*, **2014**, 89, 1030-6	7.1	13

95	Profiling of circulating exosomal miRNAs in patients with Waldenstrm Macroglobulinemia. *PLoS ONE*, **2018**, 13, e0204589	3.7	13
94	Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. *PLoS ONE*, **2013**, 8, e66982	3.7	12
93	Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. *Journal of Hematology and Oncology*, **2010**, 3, 38	22.4	12
92	Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. *Clinical Cancer Research*, **2012**, 18, 6609-22	12.9	11
91	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. *Expert Opinion on Investigational Drugs*, **2019**, 28, 445-462	5.9	10
90	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. *Blood*, **2015**, 126, 23-23	2.2	10
89	Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. *Blood Cancer Journal*, **2014**, 4, e204	7	9
88	Progression signature underlies clonal evolution and dissemination of multiple myeloma. *Blood*, **2021**, 137, 2360-2372	2.2	9
87	Epigenetic Aberrations in Multiple Myeloma. *Cancers*, **2020**, 12,	6.6	8
86	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. *Blood*, **2016**, 128, 197-197	2.2	7
85	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrm macroglobulinemia. *Blood*, **2021**, 138, 1535-1539	2.2	7
84	Epigenetics in Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 35-49	3.5	6
83	Circulating microRNAs and Their Role in Multiple Myeloma. *Non-coding RNA*, **2019**, 5,	7.1	5
82	Targeting the bone marrow in Waldenstrom macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11 Suppl 1, S65-9	2	5
81	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. *Blood Advances*, **2019**, 3, 995-1002	7.8	5
80	Candidate genes of Waldenstrm's macroglobulinemia: current evidence and research. *The Application of Clinical Genetics*, **2013**, 6, 33-42	3.1	4
79	Novel therapeutic agents in Waldenstrm's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2009**, 9, 84-6		4
78	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. *Science Advances*, **2022**, 8, eabl4644	14.3	4

77	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. *Blood*, **2014**, 124, 3431-3431	2.2	4
76	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. *Blood*, **2015**, 126, 502-502	2.2	4
75	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. *Cancers*, **2021**, 13,	6.6	4
74	The role of miRNAs in plasma cell dyscrasias. *MicroRNA (Shariqah, United Arab Emirates)*, **2014**, 2, 165-73	2.9	3
73	Role of proteasome inhibition in Waldenstrm's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2009**, 9, 94-6		3
72	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. *Blood*, **2013**, 122, 272-272	2.2	3
71	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. *Blood*, **2013**, 122, 680-680	2.2	3
70	The importance of the genomic landscape in Waldenstrm's Macroglobulinemia for targeted therapeutical interventions. *Oncotarget*, **2017**, 8, 35435-35444	3.3	3
69	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. *Blood*, **2021**, 138, 1705-1720	2.2	3
68	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. *American Journal of Hematology*, **2017**, 92, E138-E145	7.1	2
67	Key role of microRNAs in Waldenstrm's macroglobulinemia pathogenesis. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 109-11	2	2
66	The bone marrow niche in Waldenstrm's macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 118-20	2	2
65	Epigenetics in Waldenstrm's macroglobulinemia. *Epigenomics*, **2010**, 2, 691-6	4.4	2
64	The bone marrow microenvironment in waldenstrom macroglobulinemia. *Therapeutic Advances in Hematology*, **2011**, 2, 267-72	5.7	2
63	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2007**, 110, 1516-1516	2.2	2
62	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 3732-3732	2.2	2
61	Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment. *Blood*, **2010**, 116, 142-142	2.2	2
60	The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma. *Blood*, **2011**, 118, 1844-1844	2.2	2

59	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. *Blood*, **2011**, 118, 625-625	2.2	2
58	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. *Blood*, **2013**, 122, 273-273	2.2	2
57	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. *Blood*, **2016**, 128, 1137-1137	2.2	2
56	MicroRNA Signature in Waldenstrom Macroglobulinemia. *Blood*, **2008**, 112, 630-630	2.2	2
55	Molecular Pathways in Growth and Survival: Epigenomics **2017**, 67-71		1
54	Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia. *Current Cancer Drug Targets*, **2011**, 11, 1025-9	2.8	1
53	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. *Blood*, **2009**, 114, 1785-1785	2.2	1
52	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. *Blood*, **2010**, 116, 453-453	2.2	1
51	Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients. *Blood*, **2012**, 120, 3975-3975	2.2	1
50	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. *Blood*, **2012**, 120, 440-440	2.2	1
49	Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination. *Blood*, **2014**, 124, 4709-4709	2.2	1
48	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. *Blood Cancer Discovery*, **2021**, 2, 338-353	7	1
47	Epigenomics in Waldenstrom's macroglobulinaemia. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 156-160	4.2	1
46	Halting the FGF/FGFR axis leads to antitumor activity in Waldenstrm macroglobulinemia by silencing MYD88. *Blood*, **2021**, 137, 2495-2508	2.2	1
45	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. *Blood* , **2015**, 126, 1793-1793	2.2	0
44	Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2007**, 110, 2512-2512	2.2	
43	The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.. *Blood*, **2007**, 110, 2617-2617	2.2	
42	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrm Macroglobulinemia.. *Blood*, **2007**, 110, 1383-1383	2.2	

41	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. *Blood*, **2018**, 132, 55-55	2.2
40	Vascular and Stromal Contributions to Tumor Bone-Homing: Focus on Multiple Myeloma **2020**, 236-242	
39	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. *Blood*, **2014**, 124, 2051-2051	2.2
38	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. *Blood*, **2014**, 124, 3430-3430	2.2
37	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. *Blood*, **2014**, 124, 4719-4719	2.2
36	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. *Blood*, **2014**, 124, 2101-2101	2.2
35	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. *Blood*, **2014**, 124, 2056-2056	2.2
34	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. *Blood*, **2015**, 126, 1755-1755	2.2
33	A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish. *Blood*, **2015**, 126, 915-915	2.2
32	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. *Blood*, **2015**, 126, 1770-1770	2.2
31	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. *Blood*, **2016**, 128, 237-237	2.2
30	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. *Blood*, **2016**, 128, 4483-4483	2.2
29	Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia. *Blood*, **2016**, 128, 2940-2940	2.2
28	Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. *Blood*, **2009**, 114, 3843-3843	2.2
27	Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.. *Blood*, **2009**, 114, 2935-2935	2.2
26	The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.. *Blood*, **2009**, 114, 3737-3737	2.2
25	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 4911-4911	2.2
24	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 4916-4916	2.2

23	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. *Blood*, **2010**, 116, 3622-3622	2.2
22	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. *Blood*, **2010**, 116, 4035-4035	2.2
21	Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells. *Blood*, **2010**, 116, 2958-2958	2.2
20	LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 4914-4914	2.2
19	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 3620-3620	2.2
18	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. *Blood*, **2011**, 118, 471-471	2.2
17	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. *Blood*, **2011**, 118, 1804-1804	2.2
16	L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib. *Blood*, **2011**, 118, 887-887	2.2
15	Role of TORC1 and TORC2 in Multiple Myeloma. *Blood*, **2011**, 118, 1815-1815	2.2
14	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. *Blood*, **2011**, 118, 3669-3669	2.2
13	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. *Blood*, **2011**, 118, 3934-3934	2.2
12	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2728-2728	2.2
11	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. *Blood*, **2011**, 118, 2424-2424	2.2
10	CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells. *Blood*, **2012**, 120, 4009-4009	2.2
9	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. *Blood*, **2012**, 120, 3944-3944	2.2
8	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. *Blood*, **2012**, 120, 570-570	2.2
7	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/Catenin Signaling Pathway. *Blood*, **2013**, 122, 3094-3094	2.2
6	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. *Blood*, **2013**, 122, 121-121	2.2

5	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. *Blood*, **2013**, 122, 3086-3086	2.2
4	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. *Blood*, **2013**, 122, 3159-3159	2.2
3	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. *Blood*, **2013**, 122, 275-275	2.2
2	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. *Blood*, **2013**, 122, 3751-3751	2.2
1	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. *Blood*, **2013**, 122, 3093-3093	2.2